Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Victoria's Secret & Co (VSXY) Price & Performance

Abeona Therapeutics IncTrade
Victoria's Secret & CoTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Victoria's Secret & Co — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Victoria's Secret & Co trades at $96.04 (market cap $7.48B). The key difference: Victoria's Secret & Co is far larger — about 17.8× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.

ABEOVSXY
Market Cap
$421.19M$7.48B
Sector
HealthConsumer Cyclical
52-Week High
$7.45$99.97
52-Week Low
$4.17$21.34
Enterprise Value
$276.10M$10.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Victoria's Secret & Co

Victoria's Secret (VSXY) trades at $99.97, up 1.45% today and near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive earnings surprises in three consecutive quarters. Revenue remains stable at $6.23B for 2025, while net income improved to $165M. Analyst consensus is bullish with 55.6% buy ratings and a $110 high price target, supported by recent international expansion success in China and Europe.

VSXY presents growth potential through international expansion and data-driven marketing, but faces valuation concerns with a P/E of 37.5 and competitive retail pressures. The stock's current price exceeds the consensus target, suggesting near-term consolidation risk despite positive technical momentum and improving fundamentals.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Victoria's Secret & Co

Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.

Read more on VSXY